PRKN and Parkinson disease: Therefore, PGC-1α has been proposed as a therapeutic target in PD, which is further supported by the direct interaction between PGC-1α activity and the α-synuclein pathology and by the finding that Parkin controls PGC-1α expression via the proteasomal degradation of PARIS, a transcriptional repressor of PGC-1α (Shin et al., 2011).